Latest filings (excl ownership)
ARS
2023 FY
Annual report to shareholders
1 Apr 24
DEFA14A
Additional proxy soliciting materials
1 Apr 24
DEF 14A
Definitive proxy
1 Apr 24
8-K
Departure of Directors or Certain Officers
4 Mar 24
10-K
2023 FY
Annual report
15 Feb 24
8-K
Results of Operations and Financial Condition
15 Feb 24
8-K
Departure of Directors or Certain Officers
19 Jan 24
8-K
Alnylam Announces Preliminary* Fourth Quarter and Full Year 2023 Global Net Product Revenues and Provides Additional Updates
8 Jan 24
10-Q
2023 Q3
Quarterly report
2 Nov 23
8-K
Results of Operations and Financial Condition
2 Nov 23
8-K
Alnylam Announces Receipt of Complete Response Letter from U.S. FDA for Supplemental New Drug Application for Patisiran for the Treatment of the
10 Oct 23
8-K
Departure of Directors or Certain Officers
28 Sep 23
10-Q
2023 Q2
Quarterly report
3 Aug 23
8-K
Alnylam Pharmaceuticals Reports Second Quarter 2023 Financial Results and Highlights Recent Period Activity
3 Aug 23
8-K
Entry into a Material Definitive Agreement
26 Jul 23
8-K
Alnylam Announces Date of Planned FDA Advisory Committee Meeting for ONPATTRO® (patisiran) for the Treatment of the Cardiomyopathy of ATTR
30 Jun 23
8-K
Submission of Matters to a Vote of Security Holders
23 May 23
10-Q
2023 Q1
Quarterly report
4 May 23
8-K
Results of Operations and Financial Condition
4 May 23
ARS
2022 FY
Annual report to shareholders
3 Apr 23
DEFA14A
Additional proxy soliciting materials
3 Apr 23
DEF 14A
Definitive proxy
3 Apr 23
8-K
Departure of Directors or Certain Officers
8 Mar 23
S-8
Registration of securities for employees
23 Feb 23
10-K
2022 FY
Annual report
23 Feb 23
8-K
Results of Operations and Financial Condition
23 Feb 23
CT ORDER
Confidential treatment order
14 Feb 23
8-K
Alnylam Announces Preliminary* Fourth Quarter and Full Year 2022 Global Net Product Revenues and Provides Additional Updates
9 Jan 23
8-K
Alnylam Announces Updates to its Board of Directors
6 Jan 23
10-Q
2022 Q3
Quarterly report
27 Oct 22
8-K
Results of Operations and Financial Condition
27 Oct 22
8-K
Entry into a Material Definitive Agreement
16 Sep 22
8-K
Alnylam Announces Proposed Offering of $900 Million Convertible Senior Notes
13 Sep 22
8-K
Departure of Directors or Certain Officers
24 Aug 22
10-Q
2022 Q2
Quarterly report
28 Jul 22
8-K
Results of Operations and Financial Condition
28 Jul 22
8-K
Other Events
14 Jun 22
8-K
Submission of Matters to a Vote of Security Holders
23 May 22
10-Q
2022 Q1
Quarterly report
28 Apr 22
8-K
Results of Operations and Financial Condition
28 Apr 22
Latest ownership filings
3
Kevin Joseph Fitzgerald
28 Mar 24
4
Tolga Tanguler
5 Mar 24
4
Pushkal Garg
5 Mar 24
4
Jeffrey V. Poulton
5 Mar 24
4
Yvonne Greenstreet
5 Mar 24
4
PHILLIP A SHARP
1 Mar 24
4
Tolga Tanguler
29 Feb 24
4
Jeffrey V. Poulton
29 Feb 24
4
Yvonne Greenstreet
29 Feb 24
4
Pushkal Garg
29 Feb 24
4
Indrani Lall Franchini
29 Feb 24
144
Notice of proposed sale of securities
29 Feb 24
4
Pushkal Garg
20 Feb 24
4
Jeffrey V. Poulton
20 Feb 24
4
Tolga Tanguler
20 Feb 24
4
Yvonne Greenstreet
20 Feb 24
SC 13G/A
VANGUARD GROUP INC
13 Feb 24
SC 13G/A
Capital World Investors
9 Feb 24
SC 13G/A
WELLINGTON MANAGEMENT GROUP LLP
9 Feb 24
SC 13G/A
FMR LLC
9 Feb 24
4
Indrani Lall Franchini
5 Feb 24
SC 13G/A
BAILLIE GIFFORD & CO
29 Jan 24
SC 13G/A
BlackRock Inc.
26 Jan 24
4
MICHAEL W BONNEY
29 Dec 23
144
Notice of proposed sale of securities
27 Dec 23
144
Notice of proposed sale of securities
11 Dec 23
4
Pushkal Garg
7 Aug 23
4
Jeffrey V. Poulton
7 Aug 23
4
Yvonne Greenstreet
7 Aug 23
4
Akshay Vaishnaw
7 Aug 23
144
Notice of proposed sale of securities
7 Aug 23
4
MICHAEL W BONNEY
4 Aug 23
4
DAVID E I PYOTT
19 May 23
4
Charles Elliott Sigal
19 May 23
4
OLIVIER BRANDICOURT
19 May 23
4
MARGARET A HAMBURG
19 May 23
4
Colleen F Reitan
19 May 23
4
AMY W SCHULMAN
19 May 23
4
Dennis A Ausiello
19 May 23
4
Marsha Fanucci
19 May 23